Effect of additional cytogenetic abnormalities on survival in arsenic trioxide-treated acute promyelocytic leukemia Journal Article
| Authors: | Epstein-Peterson, Z. D.; Derkach, A.; Geyer, S.; Mrózek, K.; Kohlschmidt, J.; Park, J. H.; Rajeeve, S.; Stein, E. M.; Zhang, Y.; Iland, H.; Campbell, L. J.; Larson, R. A.; Poiré, X.; Powell, B. L.; Stock, W.; Stone, R. M.; Tallman, M. S. |
| Article Title: | Effect of additional cytogenetic abnormalities on survival in arsenic trioxide-treated acute promyelocytic leukemia |
| Abstract: | Frontline arsenic trioxide (ATO)-based treatment regimens achieve high rates of long-term relapse-free survival in treating acute promyelocytic leukemia (APL) and form the current standard of care. Refining prognostic estimates for newly diagnosed patients treated with ATO-containing regimens remains important in continuing to improve outcomes and identify patients who achieve suboptimal outcomes. We performed a pooled analysis of exclusively ATO-treated patients at a single academic institution and from the ALLG APML4 and Alliance C9710 studies to determine the prognostic importance of additional cytogenetic abnormalities and/or complex karyotype. We demonstrated inferior event-free survival for patients harboring complex karyotype (hazard ratio [HR], 3.74; 95% confidence interval [CI], 1.63-8.56; P = .002), but not for patients harboring additional cytogenetic abnormalities (HR, 2.13; 95% CI, 0.78-5.82; P = .142). These data support a role for full karyotypic analysis of all patients with APL and indicate a need for novel treatment strategies to overcome the adverse effect of APL harboring complex karyotype. |
| Keywords: | impact; chromosome-abnormalities; flt3 mutations; front-line therapy |
| Journal Title: | Blood Advances |
| Volume: | 6 |
| Issue: | 11 |
| ISSN: | 2473-9529 |
| Publisher: | American Society of Hematology |
| Date Published: | 2022-06-14 |
| Start Page: | 3433 |
| End Page: | 3439 |
| Language: | English |
| ACCESSION: | WOS:000817926400003 |
| DOI: | 10.1182/bloodadvances.2021006682 |
| PROVIDER: | wos |
| PMCID: | PMC9198910 |
| PUBMED: | 35349669 |
| Notes: | Article -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work